Pervasis Therapeutics
Pervasis Therapeutics is a clinical stage company offering a broad portfolio of biologically active therapeutics
About Pervasis Therapeutics
Pervasis Therapeutics, founded in 2003, was a clinical-stage biotechnology firm that operated in the regenerative medicine sector. The company was established by a distinguished group including Dr. Elazer Edelman, Dr. Robert Langer, Dr. Joseph Vacanti, and Helen Nugent, based on research partially funded by the Deshpande Center for Innovation at MIT. This founding team, composed of prominent faculty from MIT and Harvard Medical School, leveraged their deep expertise in tissue engineering and vascular biology to address unmet needs in vascular repair.
The company's core business centered on developing biologically active, cell-based therapies to improve the outcomes of common vascular interventions like angioplasties, stents, and bypass grafts. Its primary market consisted of patients suffering from vascular diseases, with a particular focus on those with end-stage renal disease (ESRD) requiring hemodialysis. Pervasis' business model revolved around the research, clinical development, and eventual commercialization of its proprietary technologies, having raised significant venture capital from investors such as Flagship Pioneering, Polaris Partners, and Highland Capital Partners.
Pervasis' flagship product was Vascugel®, a novel, allogeneic cell therapy product. Vascugel® is a cell-based therapeutic gel designed to be placed adjacent to an injured blood vessel during surgical procedures. Its key feature was the use of embedded endothelial cells that provide growth-regulatory compounds to the site of injury. This process was intended to mimic the body's natural healing pathways, promoting vascular health while reducing inflammation, thrombosis, and restenosis (the re-narrowing of the vessel). The product, which had completed Phase II clinical trials, was developed to prevent the failure of arteriovenous grafts and fistulas—critical access sites for hemodialysis patients. In a significant milestone, Pervasis Therapeutics was acquired by Shire plc in April 2012 in a deal potentially valued at up to $200 million, aimed at bolstering Shire's regenerative medicine business.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES COther financing | Aug 2009 | $17M | $70M | Polaris Partners · Flagship Pioneering · Highland Capital Partners | — |
| EARLY VCOther financing | Jan 2008 | $9.8M | $39M | Highland Capital Partners · Flagship Pioneering · Polaris Partners | — |
Growth signals
Latest recorded traffic for Pervasis Therapeutics is 0 monthly website visits, down 100% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Pervasis Therapeutics in the Cambridge ecosystem
The Pervasis Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
Series A1 investor entered at this stage
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Pervasis Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Pervasis Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










